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GENERAL INTRODUCTION 
Introduction: Analytical chemistry  
Analytical chemistry [1] is the science to analyze morphologies, compositions and 
quantities of analytical targets. These analytical results have played critical roles from the 
understanding of basic science to a variety of practical applications, such as biomedical 
applications, environmental monitoring, quality control of industrial manufacturing and 
forensic science. 
Modern analytical chemistry is dominated by instrumental analysis. There are so 
many different types of instruments today that it can seem like a confusing array of acronyms 
rather than a unified field of study. Analytical chemistry plays an increasingly important role 
in the pharmaceutical industry where, aside from QA, it is used in discovery of new drug 
candidates and in clinical applications where understanding the interactions between the drug 
and the patient are critical. 
¾ Types 
      Traditionally, analytical chemistry has been split into two main types, qualitative and 
quantitative. 
• Qualitative 
       Qualitative inorganic analysis seeks to establish the presence of a given element 
or inorganic compound in a sample or the functional group present in a organic 
compound 
• Quantitative 
        Quantitative analysis seeks to establish the amount of a given element or   
compound in a sample. 
          Analytical chemistry research is largely driven by performance (sensitivity, 
selectivity, robustness, linear range, accuracy, precision and speed) and cost (purchase, 
operation, training, time and space). 
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Classification of analytical methods [2]:  
Generally analytical methods are classified into: 
            (a)   Chemical analysis 
  (b)   Instrumental methods  
(a)  Chemical analysis: 
     These methods depend upon quantitative performance of a suitable chemical reaction and 
either measuring the amount of reagents needed to complete the reaction or ascertaining the 
amount of reaction product obtained e.g. titrimetric (acid base titration, oxidation- reduction 
titration , non-aqueous titration, complex formation), gravimetric and volumetric methods. 
(b) Instrumental methods:            
    These methods are based up on the measurement of physical properties of a substance such 
as electrical, optical and absorption and to correlate them for determination of concentration 
of analyte. These properties are being explained for development of analytical methods such 
as spectrophotometry, HPLC, GLC and polarography etc. Now a days instrumental method 
of analysis are widely accepted over the classical methods. These methods are extremely 
sensitive providing precise and detailed information from small sample materials. 
     Depending upon the nature and type of material either single or in combination, an 
appropriate method of analysis is adopted. Instrumental methods are usually much faster than 
chemical methods and are applicable at concentration far too small to be amenable to 
determination by chemical methods and find wide application in industry. 
Advantages of instrumental methods: 
¾ Small sample can be used. 
¾ High sensitivity is obtained. 
¾ Measurements obtained are reliable. 
¾ The determination is very fast. 
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¾ Even complex sample can be handled easily. 
CHROMATOGRAPHY [3] 
Introduction: 
  Chromatography (from Greek: khromatos- colour and graphos- write) is the 
collective term for a family of laboratory techniques for the separation of mixtures. It 
involves passing a mixture dissolved in a "mobile phase" through a stationary phase, which 
separates the analyte to be measured from other molecules in the mixture and allows it to be 
isolated. 
                         Chromatography may be preparative or analytical. Preparative chromatography is 
helpful to separate the components of a mixture for further use. Analytical chromatography 
normally uses smaller amounts of material and seeks to measure the relative proportions of 
analytes in a mixture.  
Chromatography techniques [4]: 
 Recently, the IUPAC has defined chromatography as; 
       “A method used primarily for the separation of the components of a sample, in which the 
components are distributed between two phases, one of which is stationary while other 
moves. The stationary phase may be a solid or a liquid supported on a solid or a gel and may 
be packed in a column, spread as a layer or distributed as a film. The mobile phase may be 
gaseous or liquid. 
Classification of chromatography techniques: 
1) According to the nature of stationary and mobile phase 
• Gas solid chromatography 
• Gas liquid chromatography 
• Liquid solid chromatography 
• Liquid liquid chromatography   
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2) According to mechanisms of separation, chromatographic methods are divided in to 
following general area 
• Adsorption chromatography 
• Partition chromatography 
• Size exclusion chromatography 
• Ion exchange chromatography 
 
          In adsorption chromatography, the analytes interact with solid stationary surface and 
are displaced with the eluent for active sites on surface. 
         Partition chromatography, results from a thermodynamic distribution between two 
liquid (or liquid like) phase. On the basis of relative polarities of stationary and mobile phase. 
Partition chromatography can be divided in to normal phase and reverse-phase 
chromatography.  
        In normal phase chromatography, the stationary bed is strongly polar in nature (e.g., 
silica gel) and the mobile phase is non polar (such as n-hexane or tetrahydrofuran) 
         Polar samples are thus retained on the polar surface of the column packing longer than 
less polar materials while in reversed-phase chromatography, the stationary bed is non 
polar (hydrophobic) in nature, while the mobile phase is polar liquid, such as mixtures of 
water and methanol or acetonitrile. Here the more non polar the materials is, the longer it will 
be retained. 
        Size exclusion chromatography involves a solid stationary phase with controlled pore 
size. Solutes are separated according to molecular size, with the large molecules unable to 
enter the pores elute first.            
        Ion–exchange chromatography, involves a solid stationary phase with anionic or 
cationic groups on the surface to which solute molecules of opposite charges are attracted. 
        In chromatographic separation, HPLC and HPTLC methods have widely been exploited 
in pharmaceutical analysis because of its simplicity, precision, accuracy and reproducibility 
of results. 
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High performance liquid chromatography (HPLC) [5]: 
        The typical HPLC separation is based on the selective distribution of analytes between a 
liquid mobile phase and an immiscible stationary phase. The sample is first introduced by 
means of an injection port in to the mobile phase stream that is delivered by a high pressure 
pump. Next, the components of this sample mixture are separated on the column, a process 
monitored with a flow through detector as the isolated components emerge from the column. 
        The HPLC is classified in to two modes depending on the relative polarity of the two 
phases, normal and reverse-phase chromatography. These are two elution types in HPLC 
they are isocratic and gradient. In isocratic elution, composition of solvents is pumped 
through the column during complete analysis is unchanged. In gradient system, eluent 
composition and strength is steadily changed during the run. 
 
INSTRUMENTATION [6] 
 
                  
                                               Typical diagram of HPLC 
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The individual components HPLC and their working functions are described below. 
 SOLVENT DELIVERY SYSTEM 
The mobile phase is pumped under pressure from one or several reservoirs and flows 
through the column at a constant rate. With micro particulate packing, there is a high-pressure 
drop across a chromatography column. Eluting power of the mobile phase is determined by 
its overall polarity, the polarity of the stationary phase and the nature of the sample 
components. For normal phase separations, eluting power increases with increasing polarity 
of the solvent but for reversed phase separations, eluting power decreases with increasing 
solvent polarity. Optimum separating conditions can be achieved by making use of mixture of 
two solvents. Some other properties of the solvents, which need to be considered for a 
successful separation, are boiling point, viscosity, detector compatibility, flammability and 
toxicity. 
The most important component of HPLC in solvent delivery system is the pump, 
because its performance directly effects the retention time, reproducibility and detector 
sensitivity. Among the several solvent delivery systems, (direct gas pressure, pneumatic 
intensifier, reciprocating etc.) reciprocating pump with twin or triple pistons is widely used, 
as this system gives less baseline noise, good flow rate reproducibility etc.  
 MOBILE PHASE 
Mobile phase used for HPLC typically are mixtures of organic solvents and water or 
aqueous buffers. Table given below lists the physical properties of organic solvents 
commonly used for HPLC. Isocratic methods are preferable to gradient methods. Gradient 
methods will sometimes be required when the molecules being separated have vastly 
different partitioning properties. When a gradient elution method is used, care must be taken 
to ensure that all solvents are miscible.  
The following points should also be considered when choosing a mobile phase: 
1. It is essential to establish that the drug is stable in the mobile phase for at least the duration 
of the analysis. 
2. Excessive salt concentrations should be avoided. High salt concentrations can result in 
precipitation, which can damage HPLC equipment. 
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3. The mobile phase should have a pH between 2.5 and pH 7.0 to maximize the lifetime of 
the column. 
4. The cost and toxicity of the mobile phase can be reduced by using methanol instead of 
acetonitrile. 
5. Chemicals such a trifluoroacetic acid, acetic acid or formic acid should be minimized and 
which may prevent detection of products without chromophores at 220 nm. Carboxylic 
acid modifiers can be frequently replaced by phosphoric acid, which does not absorb 
above 200 nm. 
6.  Volatile mobile phases are presented to facilitate collection of products and in LC-MS 
analysis. Volatile mobile phases include ammonium acetate, ammonium phosphate, 
formic acid, acetic acid and trifluoroacetic acid. 
 
Ionizable compounds in some cases can present some problems when analyzed by 
reverse phase chromatography. Two modifications of the mobile phase can be useful in 
reverse phase HPLC for ionizable compounds. One is called ion suppression and other is ion 
pairing chromatography. In both techniques, a buffer is used to ensure that the pH of the 
solution is constant and usually at least 1.5 pH units from a pKa of the drug to ensure that one 
form of the drug predominates. In ion suppression chromatography, the pH of the aqueous 
portion of the mobile phase is adjusted to allow the neutral form of the drug to predominate. 
This ensures that the drug is persistent in only one form and results in improvement of the 
peak shape and consistency of retention times. In ion pairing chromatography, the pH of the 
mobile phase is adjusted so that the drug is completely ionized. If necessary to improve peak 
shape or lengthen retention time, an alkyl sulfonic acid salt or bulky anion such as 
trifluoroacetic acid is added to the ion pair to cationic drugs or a quaternary alkyl ammonium 
salt is added to ion-pair to anionic drugs. Ion pairing chromatography also allows the 
simultaneous analysis of both neutral and charged compounds 
SOLVENT DEGASSING SYSTEM 
The constituents of the mobile phase should be degassed and filtered before use. 
Several methods are employed to remove the dissolved gases in the mobile phase. They 
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include heating and stirring, vacuum degassing with an aspirator, filtration through 0.45 µ 
filter, vacuum degassing, helium purging, ultra sonification or purging or combination of 
these methods. HPLC systems are also provided an online degassing system, which 
continuously removes the dissolved gases from the mobile phase. 
GRADIENT ELUTION DEVICES 
HPLC columns may be run isocratically, i.e., with constant eluent or they may be run 
in the gradient elution mode in which the mobile phase composition varies during run. 
Gradient elution over comes the problem of dealing with a complex mixture of solutes.  
 COLUMNS 
The heart of the system is the column. The choice of common packing material and 
mobile phases depends on the physical properties of the drug. Many different reverse phase 
columns will provide excellent specificity for any particular separation. It is therefore best to 
routinely attempt separations with a standard C8 or C18 column and determine if it provides 
good separations. If this column does not provide good separation or the mobile phase is 
unsatisfactory, alternate methods or columns should be explored. Reverse phase columns 
differ by the carbon chain length, degree of end capping and percent carbon loading.  Diol, 
cyano and amino groups can also be used for reverse phase chromatography. 
  SAMPLE INTRODUCTION SYSTEM 
Two means for analyte introduction on the column are injection into a flowing stream 
and a stop flow injection. These techniques can be used with a syringe or an injection valve. 
Automatic injector is a microprocessor-controlled version of the manual universal injector. 
Usually, up to 100 samples can be loaded in to the auto injector tray. The system parameters 
such as flow rates, gradient, run time, volume to be injected, etc. are chosen, stored in 
memory and sequentially executed on consecutive injections.  
 LIQUID CHROMATOGRAPHIC DETECTORS 
 The function of the detector in HPLC is to monitor the mobile phase as it emerges 
from the column. Generally, there are two types of HPLC detectors, bulk property detectors 
and solute property detectors.  
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a. Bulk property detectors: These detectors are based on differential measurement of a 
property, which is common to both the sample and the mobile phase. Examples of such 
detectors are refractive index, conductivity and dielectric constant detectors. 
b. Solute property detectors: Solute property detectors respond to a physical property of the 
solute, which is not exhibited by the pure mobile phase. These detectors measure a 
property, which is specific to the sample, either with or without the removal of the mobile 
phase before the detection. Solute property detectors which do not require the removal of 
the mobile phase before detection include spectrophotometric (UV or UV-Visible) 
detector, fluorescence detectors, polarographic, electro-chemical and radio activity 
detectors, where as flame ionization detector and electron capture detector both require 
removal of the mobile phase before detection. 
UV-Visible and fluorescent detectors are suitable for gradient elution, because many 
solvents used in HPLC do not absorb to any significant extent. 
 TEMPERATURE 
Room temperature is the first choice. Elevated temperatures are sometimes used to 
reduce column pressure or enhance selectivity. Typically, temperatures in excess of 600C are 
not used. 
 RETENTION TIME 
Due to a number of samples assayed in the course of preformulation study, it is 
advisable to have as short a retention time as possible. However, the retention time should be 
sufficiently long enough to ensure selectivity. When choosing the optimum mobile phase, 
considerations should be given to the retention time of degradation products, so that these 
compounds do not elute in the solvent front or remain in the column.  
 HPLC METHOD DEVELOPMENT [7] 
A good method development strategy should require only as many experimental runs 
as are necessary to achieve the desired final result. Finally method development should be as 
simple as possible, and it should allow the use of sophisticated tools such as computer 
modeling. During initial method development, a set of initial conditions (detector, column, 
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mobile phase) is selected to obtain the first “scouting” chromatograms of the sample. In most 
cases, these are based on reversed-phase separations on a C18 column with UV detection.  
The important factors, which are to be taken into account to obtain reliable 
quantitative analysis, are 
1. Careful sampling and sample preparation.  
2. Appropriate choice of the column. 
3. Choice of the operating conditions to obtain the adequate resolution of the 
mixture. 
4. Reliable performance of the recording and data handling systems. 
5. Suitable integration/peak height measurement technique. 
6. The mode of calculation best suited for the purpose. 
7. Validation of the developed method. 
SAMPLE PREPARATION 
 Samples comes in various forms               
• Solutions ready for injection 
• Solutions that require dilution, buffering, addition of an internal standard or other 
volumetric manipulation 
• Solids must be dissolved or extracted 
• Samples that require pretreatment to remove interferences and/or protect the column 
or equipment from damage. 
 Most samples for HPLC analysis require weighing and /or volumetric dilution before 
injection. Best results are often obtained when the composition of the sample solvent is close 
to that of the mobile phase since this minimizes baseline upset and other problems. 
 Some samples require a partial separation (pre-treatment) prior to HPLC, because of 
the need to remove interferences, concentrate sample analytes or eliminate “column killers”.  
        In many cases the development of an adequate sample pre-treatment can be challenging 
for achieving a good HPLC separation. The samples may be of two types, regular or special. 
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The regular samples are typical mixtures of small molecules (<2000Da) that can be separated 
by normal starting conditions.  
CHOICE OF THE COLUMN [8] 
Selection of the column is the first and the most important step in method development. 
The appropriate choice of separation column indicates three different approaches. 
¾ Selection of separation.  
¾ The particle size and nature of the column packing. 
¾ The physical parameters of the column i.e. the length and the diameter. 
Some of the important parameters considered while selecting chromatographic columns 
are 
¾ Length and diameter of the column  
¾ Packing material  
¾ Shape of the particles 
¾ Size of the particles 
¾ % of Carbon loading  
¾ Pore volume 
¾ Surface area  
¾ End capping  
                             In this case, the column selected had a particle size of 5 µm and an internal 
diameter of 4.6 mm. The column is selected depending on the nature of the solute and the 
information about the analyte. Reversed phase mode of chromatography facilities a wide 
range of columns covering wide range of polarities by cross linking silanol groups with alkyl 
chains like like dimethyl silane (C2), butylsilane (C4), octylsilane(C8), octadecylsilane 
(C18),base deactivated silane (C18), phenyl, cyanoproply (CN), nitro, amino etc. Silica based 
columns with different cross linkings in the increasing order of Polarity are as follows:  
<…………. Non-polar …………… moderately polar…………. Polar. ……> 
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C18 < C8 < C6 < Phenyl < Amino < Cyano<nitrile < Silica 
C18 was choosen for this study since it is most retentive one. The sample manipulation 
becomes easier with this type of column. 
Generally longer column as provide better separation due to higher theoretical plate numbers. 
As the particle size decreases the surface area available for coating increases. Columns with 5 
µm particle size give the best compromise of efficiency, reproducibility and reliability. In this 
case, the column selected had a particle size of 5 µm and an internal diameter of 4.6 mm peak 
shape is equally important in method development. Columns that provide symmetrical peaks 
are always preferred while peaks with poor asymmetry can result in,  
• In accurate plate number and resolution measurement 
• Imprecise quantitation  
• Degraded and undetected minor bands in the peak tail  
• Poor retention reproducibility  
  A useful and practical measurement of peak shape is peak asymmetry factor and peak 
tailing factor. Peak asymmetry is measured at 10 % of full peak height and peak tailing factor 
at 5 %. Reproducibility of retention times and capacity factor is important for developing a 
rugged and repeatable method. 
A column which gives separation of all the impurities and degradants from each other and 
from analyte peak and which is rugged for variation in mobile phase shall be selected. 
SELECTION OF COLUMN TEMPERATURE 
 Chromatographic separations are carried out at ambient temperature. The increase in 
column temperature generally will result in reduction of asymmetry and peak retention. The 
column temperature between 30°c – 80°c is shall be adopted if necessary. If a column 
temperature above 80°c is required, packing material which can with stand to that 
temperature was preferable. 
 SELECTION OF SOLVENT DELIVERY SYSTEM 
                     Chromatographic separation with isocratic elution is always preferable. 
However, gradient elution is powerful tool in achieving separation between closely eluting 
compounds or compounds with highly differing polarities. 
 The important future of gradient elution is that the polarity and ionic strength of the 
mobile phase can be changed during run. The mobile phases are introduced into column by 
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two different ways, low pressure and high pressure gradient systems. Low pressure gradient 
can be adopted when not more than 80% of organic phase is to be pumped or vice-versa. 
While optimizing gradient elution especially low viscous solvents like acetonitrile and 
phosphate buffer, it is recommended to mix about 10% aqueous portion  preferably the same 
buffer used in mobile phase to avoid pumping problems. 
  The gradient programme which is rugged for organic phase up to 10% variation and 
up to 0.2 ml variation in flow rate was selected.   
 SELECTION OF MOBILE PHASE 
                        The primary objective in selection and optimization of mobile phase is to 
achieve optimum separation of all impurities and degradants from each other and from 
analyte peak. 
 In liquid chromatography, the solute retention is governed by the solute distribution 
factor, which reflects the different interactions of the solute-stationary phase, solute-mobile 
phase, and mobile phase-stationary phase. For a given stationary phase, the nature and the 
composition of which has to be judiciously selected in order to get appropriate and required 
solute retention. The mobile phase has to be adapted in terms of elution strength (solute 
retention) and solvent selectivity (solute separation). Solvent polarity is the key word in 
chromatographic separations since a polar mobile phase will give rise to low solute retention 
in normal phase and high solute retention in reverse phase LC. The selectivity will be 
particularly altered if the buffer pH is close to the pKa of the analytes. The following are the 
parameters, which shall be taken into consideration while selecting and optimizing the mobile 
phase. 
• Buffer and its strength 
• pH of the buffer or pH of the mobile phase 
• Mobile phase composition 
 pH of the buffer:  
 pH plays an important role in achieving the chromatographic separations as it 
controls the elution properties by controlling the ionization characteristics. Experiments were 
conducted using buffers having different pH to obtain the required separations.  
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It is important to maintain the pH of the mobile phase in the range of 2.0 to 8.0 as most 
columns does not withstand to the pH which are outside this range. This is due to the fact that 
the siloxane linkage area cleaved below pH 2.0 while pH valued above 8.0 silica may 
dissolve.  
D. MOBILE PHASE COMPOSITION 
 Most chromatographic separations can be achieved by choosing the optimum mobile 
phase composition. This is due to the fact that fairly large amount of selectivity can be 
achieved by choosing the qualitative and quantitative composition of aqueous and organic 
portions. Most widely used solvents in reverse phase chromatography are methanol and 
acetonitrile. Experiments should be conducted with mobile phases having buffers with 
different pH and different organic phases to check for the best separations of analyte peak. A 
mobile phase which gives separation of analyte peak and which is rugged for variation of 
both aqueous and organic phase by at least ± 0.2% of the selected mobile phase composition 
is used. 
SELECTION OF FLOW RATE 
 Generally flow rate shall not be more than 2.0 ml/min. the flow rate shall be selected 
based on the following data. 
• Retention time 
• Column back pressure 
• Resolution between the peaks 
• Peak symmetries 
 The flow rate which gives least retention times, good peak symmetries, least back pressures 
and better separation will be selected. 
SELECTION OF DETECTOR 
 The detector was chosen depending upon some characteristic property of the analyte 
like UV absorbance, florescence, conductance, oxidation, reduction etc. The characteristics 
that are to be fulfilled by a detector to be used in HPLC determination are, 
• High sensitivity facilitating trace analysis  
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• Negligible baseline noise to facilitate lower detection  
• Large linear dynamic range 
• Low dead volume 
• Ease in calibration and standardization 
• Inexpensive to purchase and operate 
Pharmaceutical ingredients do not absorb UV light equally, so that selection of 
detection wavelength is important. An understanding of the UV light absorptive properties of 
the organic impurities and the active pharmaceutical ingredient is very helpful. Generally LC 
equipped with PDA detector was the first choice. UV source like mercury vapour lamp is 
most widely used because majority of the compounds of pharmaceutical interest absorb at 
250 – 270 nm and this lamp has an intense line spectrum at this region. 
For the greatest sensitivity λmax should be used. Ultra violet wavelengths below 
200nm should be avoided because detector noise increases in this region. Higher wavelengths 
give greater selectivity. 
OPTIMIZATION OF HPLC METHOD 
 During the optimization stage, the initial sets of conditions that have evolved from the 
first stages of development are improved or maximized in terms of resolution and peak shape, 
plate counts, asymmetry, capacity factor, elution time, detection limits, limit of quantitation 
and overall ability to quantify the specific analyte of interest. 
Optimization of a method can follow either of two general approaches: 
• Manual 
• Computer driven 
The manual approach involves varying one experimental variable at a time, while 
holding all other constant and recording changes in response. The variables might include 
flow rate, mobile or stationary phase composition, temperature, detection wavelength and PH. 
This univariate approach to system is slow, time consuming and potentially expensive. 
However, it may provide a much better understanding of the principles and theory involved 
and of interactions of the variables. 
 In the second approach, computer driven automated method development, efficiency 
is optimized while experimental input is minimized. Computer driven automated approaches 
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can be applied to many applications. In addition, they are capable of significantly reducing 
the time, energy and cost of all instrumental method development.  
PERFORMANCE CALCULATIONS: 
 Carrying out system suitability experiment does the performance calculations. System 
suitability experiments can be defined as tests to ensure that the method can generate results 
of acceptable accuracy and precision. The requirements for system suitability are usually 
developed after method development and validations have been completed. 
 The criteria selected will be based on the actual performance of the method as 
determined during its validation. For example, if sample retention times form part of the 
system suitability criteria, their variation SD can be determined during validation. 
System suitability might then require that retention times fall within a ±3 SD range during 
routine performance of the method. 
The RSD of peak height or area of five injections of a standard solution is normally 
accepted as one of the standard criteria. For assay method of a major component, the RSD 
should typically be less than 1% for these five respective injections. 
The plate number and/ or tailing factor are used if the run contains only one peak. For 
chromatographic separations with more than one peak, such as an internal standard assay or 
an impurity method expected to contain many peaks, some measure of separations such as RS 
is recommended. Reproducibility of tR or k value for a specific compound also defines 
system performance. 
A. COLUMN EFFICIENCY& PLATE NUMBER 
The number of theoretical plates or plate number is a measure of column efficiency. 
An efficient column produces sharp peaks and can separate many sample components in a 
relatively short time. Theoretical plates (N) are defined as the square of the ratio of the 
retention time divided by the standard deviation of the peak (σ). 
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   Another way to express efficiency of column is by calculating height equivalents of 
theoretical plates (HETP). 
                                                               h = L/n 
Where h = HETP; L = Length of the column; n = number of theoretical plates. 
 Lower the HETP, higher is the efficiency of the column, i.e., higher the theoretical 
plates more efficient the column. 
B. RESOLUTION 
The goal of most HPLC analyses is the separation of one or more analytes in the sample from 
all other components present. Resolution (Rs) is a measure of the degree of separation of two 
adjacent analytes. Rs is defined as the difference in retention times of the two peaks divided 
by the average peak width. The resolution of two adjacent peaks can be calculated by using 
the formula 
                                       
   
                            Where t1 and t2 are retention times of the adjacent peaks and  
                            W0.5,1 and W0.5,2 are the width of the peaks at half height. 
                             RS  = 2.0 or greater is a desirable target for method development. 
 
¾ The retention factor k is given by the equation 
                                                  k= (tR – t0  ) / t0 
        Where tR is the band retention time and t0 is the column dead time. 
 
¾ The peak symmetry can be represented in terms of peak asymmetry factor and peak 
tailing factor which can be calculated by using the following formulae 
                                       Peak asymmetry factor = B/A 
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     Where ‘B’ is the distance at 50% peak height between leading edge to the 
perpendicular drawn from the peak maxima and ‘A’ is the width of the peak at half the 
peak height. 
             According to USP (2000) Peak-tailing factor can be calculated by using the formula 
                                                       T = W0.05/2 f 
          Where W0.05 is the width of the peak at 5% height and f is the distance from the 
peak maximum to the leading edge of the peak, the distance being measured at a point 
50% of the peak height from the base line. 
ANALYTICAL METHOD VALIDATION [9, 10,11] 
              Method validation can be defined as per ICH “Establishing documented evidence, 
which provides a high degree of assurance that a specific activity will consistently produce 
a desired result or product meeting its predetermined specifications and quality 
characteristics”. 
                  Method validation is an integral part of the method development; it is the process 
by which a method is tested by the developer or user for reliability, accuracy and precision of 
its intended purpose and demonstrating that analytical procedures are suitable for their 
intended use that they support the identity, quality, purity, and potency of the drug substances 
and drug products. Data thus generated become part of the method validation package 
submitted to Center for Drug Evaluation and Research (CDER). Simply, method validation is 
the process of proving that an analytical method is acceptable for its intended purpose. 
Data that are generated for acceptance, release, stability or pharmacokinetic will only be 
trustworthy if the methods used to generate the data are reliable. The process of validation and 
method design also should be clearly in the development cycle before important data are 
generated. Validation should be on going in the form of re-validation with method changes. 
Though many types of HPLC techniques are available, the most commonly used method, the 
reversed-phase HPLC with UV detection, is selected to illustrate the parameters for validation. 
The criteria for the validation of this technique can be extrapolated to other detection methods 
and chromatographic techniques. For acceptance, release or stability testing, accuracy should 
be optimized since the need to show deviation from the actual or true value is of the greatest 
concern. 
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                    All the variables of the method should be considered, including sampling 
procedure, sample preparation, chromatographic separation, and detection and data 
evaluation. For chromatographic methods used in analytical applications there is more 
consistency in validation practice. The Q (2) R1 of ICH guidelines for validation for 
analytical procedures includes the following parameters. 
Method validation: 
          This process consists of establishments of the performance characteristics and the 
limitation of the method. 
             Method performance parameters are determined using equipment that is  
1. Within specification 
2. Working correctly 
3. Adequately calibrated 
Method validation is required when: 
• A new method is being developed. 
• Revision of the established method. 
• When established method are used in different laboratories and by different analysts 
etc. 
• Comparison of methods. 
• When quality control indicates method changes. 
Performance characteristics examined when carrying out method validation are:  
1. Accuracy/precision 
2. Repeatability/Reproducibility 
3. Linearity /Range 
4. Limit of detection (LOD)/Limit of quantification 
5. Selectivity/Specificity 
6. Robustness/Ruggedness 
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A) Accuracy: 
           The accuracy of an analytical procedure express the closeness of agreement between 
the value, which is accepted either as a conventional true value or an accepted reference value 
and the value found. 
Determination of accuracy: 
        The accuracy may be determined by application of analytical method to an analyte of 
known purity (example: reference standard) and also by comparing the results of the method 
with those obtained using an alternate procedure that has been already validated. 
        Accuracy is calculated as the percentage of recovery by the assay of the known added 
amount of the analyte in the sample or the difference between the mean and accepted true 
value together with confidence intervals. 
        The ICH guidelines recommended to take minimum of 3 concentration levels covering 
the specified range and 3 replicate of each concentration are analysed (totally 3×3=9  
determination). 
B) Precision: 
        The precision of an analytical procedure express the closeness of agreement between a 
series of measurements obtained from multiple sampling of the same homogenous sample 
under the prescribed conditions. Precision of analytical procedure is usually expressed the 
variance, standard deviation or co-efficient of variation of a series of measurements. 
System precision: 
         A system precision was evaluated by measuring the peak response of naratriptan for six 
replicate injection of the standard solution prepared as per the proposed method. 
Method precision: 
        The method precision was determined by preparing the sample of a single batch of 
naratriptan Hcl tablet formulation six times and analyzing as per the proposed method. 
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Determination of precision: 
        The procedure is applied repeatedly to separate identical sample drawn from the 
homogeneous batch of material and measured by the scatter of individual results from the 
mean and expressed as the standard deviation or as the co-efficient of variation (relative 
standard deviation). 
C) Specificity: 
     ICH document divides specificity in to two categories. 
• Identification tests 
• Assay / impurity tests 
 
        Specificity is the ability to assess unequivocally the analyte in the presence of 
components, which may be expected to be present. Typically these might include impurities, 
degradeants, matrix, etc. lack of specificity of an individual analytical procedure may be 
compensated by other supporting analytical procedures. 
Identification test: 
        It is demonstrated by the ability to discriminate between compounds of closely related 
structures or by comparison to known reference materials. Use of positive and negative 
control is recommended. 
Assay impurity test:  
        It is demonstrated by resolution of the two closest eluting compounds. If impurities are 
available it has to be shown that the assay is unaffected by the presence of spiked material.If 
impurities are not available the test results are compared to a second well characterized 
method. 
 
Determination of specificity: 
        When chromatographic procedures are used representative chromatograms should be 
presented to demonstrate the degree of specificity. Samples generated by stress testing of the 
drug substance using acid and base hydrolysis, temperature, photolysis and mass 
spectrometry may be useful to show that the chromatographic peak is not attributable to more 
than one component. 
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D) Selectivity: 
        It is a procedure to detect qualitatively the analyte in the presence of compounds that 
may be expected to be present in the sample matrix or the ability of a separative method to 
resolve different compounds. It is the measure of the relative method location or two peaks. 
Determination of selectivity: 
        Selectivity is determined by comparing the test results obtained on the analyte with and 
without addition of potentially interfering material. When such components are either 
unidentified or un available a measure of selectivity can be obtained by determining the 
recovery of a standard addition of pure analyte to a material containing a constant level of the 
other compounds. 
  
E) Sensitivity: 
        Sensitivity is the capacity of the test procedure to record small variation in 
concentration. It is the slope of the calibration curve. 
F) Limit of detection: 
        The limit of detections is the lowest concentration of the analyte in a sample that can be 
detected but not necessarily determined in quantitatively using a specific method under the 
required experiment conditions such a limit is expressed in terms of a concentration of 
analyte (example: µg/ml in the sample) 
        Measurement based on 
• Signal to noise ratio 
• Visual evaluation (relevent chromatogram acceptable) 
• The standard deviation of the response and the slope. 
 
                                                  LOD =  ଷ.ଷ ஢ 
ୗ
 
                                         Where 
                                                  σ  = The standard deviation of the response 
                                                  S  = The slope of the calibration curve (of the analyte) 
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G) Limit of quantification: 
      The LOQ is the lowest concentration of analyte in a sample, which can quantitatively 
determined that might be measured with an acceptable level of accuracy and precision under 
the stated operational conditions of the method. LOQ can very with the type of method 
employed and nature of the sample. Based on the standard deviation of the response and the 
quantitation limit may expressed as   
                                                 LOQ  = ଵ଴ ఙ
ୗ
 
                                          Where  
                                                  σ   = The standard deviation of the response 
                                                  S    = The slope of the calibration curve 
Measurement: 
          For instrumental and non- instrumental methods the quantitation limit is generally 
determination by the analysis of the samples with known concentration of the analyte and by 
establishing the minimum level at which the analyte can be determined with acceptable 
accuracy and precision. 
          In case of instrumental methods that exhibit back ground noise the ICH document 
describes to compare measured signals from samples with known concentration of analyte 
with those of blank samples. A typically acceptable signal to noise ratio is 10:1. 
H) Linearity and range:  
          Linearity is the ability of the method to obtain test results that are directly proportional 
to the analyte concentration within a given range. 
Range: 
          Range of analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample ( including concentrations) for which it has been 
demonstrated that the analytical procedure has a suitable level of precision, accuracy and 
linearity. 
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Measurement: 
          A range of standards should be prepared containing at least 5 different concentrations 
of analyte, which are approximately evenly spaced and span 50 -150 % of the label claim. 
          At least 6 replicates per concentration to be studied. Plot a graph of concentration (on 
x- axis) Vs mean response (on y- axis). Calculate the regression equation, y- intercept and 
correlation co-efficient. Plot another graph of concentration (on x-axis) Vs response ratio 
(replicate response divided by concentration,(on y-axis). 
          The range of the method is validated by verifying that the analytical method provides 
acceptable precision, accuracy and linearity when applied to samples containing analyte at 
the extreme of the range as well as within the rage. 
I) Ruggedness: 
          Ruggedness is the degree of reproducibility of test results obtained by the analysis of 
the same samples under a variety of test conditions such as different laboratories, analyst, 
instruments, reagent lots, elapsed assay times, temperature, days etc. 
          It can be expressed as lack influence of the operation and environmental variable on the 
test results of the analytical method. 
Determination: 
          By analysis of aliquots from homogenous lot in different laboratories by different 
analyst using different operational and environmental condition that may differ but are still 
within specified parameter. 
J) Robustness: 
          It is measure of capacity of an assay to remain unaffected by small but deliberate 
variation in method parameters and provide an indication of its reliability in normal usage 
degradation and variation in chromatography columns, mobile phase and inadequate method 
development are common causes of lack of robustness. 
Determination of robustness: 
          Method characteristics are assessed when one or more operating is varied by following 
certain designs. In case of liquid chromatography, examples of typical variation are 
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• Influence of variation of pH in a mobile phase 
• Influence of variation in mobile phase 
• Influence of variation in nm  
• Different columns (different lots and suppliers) 
• Temperature 
• Flow rate 
System suitability specification and tests: 
          It is essential for the assurance of quality performance of chromatographic system. The 
accuracy and the precision of HPLC data collected, which begins with a well behaved 
chromatographic system. The system suitability parameter and tests are the parameters that 
help in achieving this purpose. Suitability parameters are 
1. Capacity factor 
2. Precision / injection repeatability 
3. Relative retention 
4. Resolution 
5. Tailing factor 
6. Theoretical plate number 
         System suitability is the checking of a system to ensure system performance before or 
during the analysis of unknowns. Parameters such as plate count, tailing factors, resolution 
and reproducibility (%RSD retention time and area for six repetitions) are determined and 
compared against the specifications set for the method. These parameters are measured 
during the analysis of a system suitability "sample" that is a mixture of main components and 
expected by-products. Table.no.1 lists the terms to be measured and their recommended 
limits obtained from the analysis of the system suitability sample as per current FDA 
guidelines on "Validation of Chromatographic Methods". 
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Table-1 
 System Suitability Parameters and Recommendations 
Parameter Recommendation  
Capacity Factor (k’) k’>2.0 
Repeatability RSD < 1% for N > 5 is desirable. 
Theoretical Plates (N) N > 2000 
Resolution (Rs) Rs > 2 between the peak of interest and the closest eluting 
potential interferent (impurity, excipient, degradation product, 
internal standard, etc. 
Tailing Factor (T) T < 2 
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DRUG PROFILE 
Naratriptan Hcl 
Chemical properties [12]: 
IUPAC name: N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide mono 
hydrochloride. 
Empirical Formula: C17H25N3O2S•HCl 
Molecular weight: 371.93 
Structure: 
 
 
Appearance: white to pale yellow powder 
Solubility: Freely soluble in water, soluble in methanol and organic solvents 
Category [13a]: Anti-migraine 
Mechanism of action [13b]: Naratriptan binds with high affinity to 5-HT1D and 5-
HT1B receptors. The therapeutic activity of naratriptan in migraine is generally attributed to 
its agonist activity at 5-HT1D/1B receptors.  
Pharmacokinetics [13b]: 
Naratriptan tablets are well absorbed, with about 70% oral bioavailability. Following 
administration of a 2.5-mg tablet orally, the peak concentrations are obtained in 2 to 3 hours. 
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After administration of 1- or 2.5-mg tablets, the Cmax is somewhat (about 50%) higher in 
women than in men. During a migraine attack, absorption was slower, with a Tmax of 3 to 4 
hours. Food does not affect the pharmacokinetics of naratriptan. Naratriptan displays linear 
kinetics over the therapeutic dose range. 
Naratriptan is predominantly eliminated in urine, with 50% of the dose recovered unchanged 
and 30% as metabolites in urine. In vitro, naratriptan is metabolized by a wide range of 
cytochrome P450 isoenzymes into a number of inactive metabolites. 
The mean elimination half-life of naratriptan is 6 hours. The systemic clearance of naratriptan 
is 6.6 ml/min/kg. The renal clearance (220 ml/min) exceeds glomerular filtration rate, 
indicating active tubular secretion. Repeated administration of naratriptan tablets does not 
result in drug accumulation. 
Contraindication [12]: 
• Hypersensitivity to drug or its components 
• Hemiplegic or basilar headaches 
• Severe renal, cardiovascular or hepatic impairment 
• History of cerebrovascular or peripheral vascular conditions 
• Ischemic bowel disease 
• Uncontrolled hypertension 
• Use of ergot-type drugs (such as dihydroergotamine) and other 5-HT1 agonists within 24  
   hours          
• MAO inhibitor use within past 14 days 
Dose [13a]: 1 or 2.5 mg as single dose; may be repeated in 4 hours. 
Drug interactions [13a]: 
• Drug-drug: Ergot-type compounds (dihydroergotamine, methysergide): prolonged 
vasospastic reaction 
• Hormonal contraceptives: increased naratriptan blood level and effects 
• MAO inhibitors: increased systemic exposure to naratriptan, increased risk of adverse 
reactions 
• Selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination 
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• Sibutramine: serotonin syndrome  
• Drug-herbs: S-adenosylmethionine (SAM-e), St. John's wort: increased risk of 
adverse serotonergic effects 
• Drug-behaviours: Cigarette smoking: increased naratriptan metabolism 
Adverse effects [13a]: 
• CNS: dizziness, drowsiness, malaise, fatigue, paresthesia 
• CV: coronary artery vasospasm, myocardial infarction, ventricular fibrillation or 
tachycardia 
• GI: nausea, vomiting  
• Other: pain or pressure sensation in throat or neck 
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REVIEW OF LITERATURE 
Sneha. B. et. al[14] ., reported a simple, precise, rapid, and reproducible RP -HPLC method 
and validated for the determination of naratriptan Hydrochloride in pharmaceutical dosage 
form. Separation was achieved under optimized chromatographic condition on a kromasil C18 
(ODS) column (250 X 4.6 mm i.d., particle size 5μ). The mobile phase consisted of 
methanolic phosphate buffer at pH 3.2 and acetonitrile in the ratio of 60: 40 v/v. An isocratic 
elution at a flow rate of 0.8 ml/ min at ambient temperature was used. The detection was 
carried out at 223 nm. The retention time of naratriptan was found to be at 3.1 min. The 
calibration curve was linear in the concentration range of 10–60 μg/ ml.  
Madhavi. B. et. al[15] ., reported a simple, sensitive, precise and specific reverse phase high 
performance liquid chromatographic method and validated for the determination of 
naratriptan hydrochloride in tablet dosage forms. The HPLC separation was carried out by 
reverse phase chromatography on purospher star C18 column (150×4.6mm), 5µm particle size. 
A mobile phase consisted of 0.01M triethylamine buffer pH 3.0: methanol (80:20%, v/v). 
Buffer: acetonitrile mixture in the ratio (70:30% v/v) was used as diluent (in isocratic mode at 
a flow rate of 1.5ml/min). The detection was monitored at 225 nm. The calibration curve for 
naratriptan hydrochloride was linear from 10 to 80µg/ml. The proposed method had adequate 
sensitivity, reproducibility and specificity for the determination of naratriptan hydrochloride 
in tablet dosage forms.  
Kuldeep Patel. et. al [16]., reported a novel stability-indicating ultra-performance liquid 
chromatographic assay method and validated for naratriptan and its degradant products. An 
isocratic UPLC method was developed to separate the drug from the degradation products, 
using an acquity UPLC BEH C18 (50 mm x 2.1 mm) column and mixture of water:  
acetonitrile (pH3.4) (60:40) as mobile phase. The flow rate was kept 0.3 ml/ min and the 
detection was carried out at 224 nm.  
Kumara Swamy. G. et. al[17]., reported a  simple efficient, precise and accurate 
spectroscopic method and validated for quantitative estimation of naratriptan hydrochloride 
in bulk and pharmaceutical dosage form. Naratriptan solution was scanned in  the UV range 
(200-400 nm) in a 10 mm quartz cell in a double beam UV spectrophotometer and the λmax  
of  naratriptan was found  to be 223 nm. The method obeyed Beer’s law in the 
concentration range from 2-12 µg/ml.  
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Balasekhara Reddy Challa. et. al [18]., reported a specific liquid chromatography-tandem 
mass  spectrometry (LC-MS/MS) method for the quantification of  naratriptan (NTP) in 
human plasma using  naratriptan -d3 (NPD3) as an internal standard. Chromatographic 
separation was performed on a Zorbax SB-C18, 75×4.6 mm, 3.5 µm column with an isocratic 
mobile phase composed of  0.1%  formic acid: acetonitrile (50:50 v/v) , at a flow rate of 0.6 
ml/min.NTP and NPD3 were detected with proton adducts at m/z  336.5 and 339.4 in selected 
reaction monitoring (SRM) positive mode, respectively. The liquid-liquid extraction method 
was used to extract the NTP and NPD3.  
Manish Yadav. et. al[19]., reported a simple, sensitive, selective and rapid high performance 
liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) method and validated 
for the quantification of naratriptan, using sumatriptan as internal standard (IS). The 
method concerned liquid–liquid extraction of naratriptan and IS in methyl-tert-butyl ether 
and dichloromethane mixture from 100 µl human plasma.  The chromatographic separation 
was achieved on ACE C18 (50mm X 2.1mm, 5µm) analytical column under isocratic 
conditions, using 0.1% acetic acid and acetonitrile (15:85 v/v) at a flow rate of 0.4 
ml/min. The parent product ion transitions for naratriptan (m/z 336.10-98.06) and IS (m/z 
296.09-251.06) were monitored on a triple quadrupole mass spectrometer, operating in the 
multiple reaction monitoring (MRM) and positive ion mode. The linearity of the method for 
naratriptan was ascertained in the range of 103-20690 pg/ml with the analysis time of 1.5 min 
 
Velasco-Aguirre. C. et. al[20]., reported that naratriptan exhibited an anodic response in 
aqueous media over a broad pH range (pH 2–12), as determined by differential pulse 
voltammetry and cyclic voltammetry using glassy carbon electrodes. This response was 
irreversible in nature, diffusion-controlled and probably caused by the oxidation of the 
naratriptan indole moiety. The differential pulse voltammetry technique was performed in 
0.1 mol/min Britton–Robinson buffer (pH 3), for the quantification of naratriptan in 
formulation.  
  
Duléry. BD. et. al [21]., reported a liquid chromatographic-electrospray-mass spectrometric 
(LC-ESI-MS) assay to compare the pharmacokinetics of these three antimigraine compounds 
MDL−74721, sumatriptan and naratriptan. The concentration of each parent drug was 
determined using a solid-phase extraction and LC-ESI-MS analysis demonstrating the high 
sensitivity and specificity of the methods down to subnanogram levels in rabbit plasma 
samples.  
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Murthy.T.E.G.K. et. al[22]., reported a simple, sensitive, selective, accurate, precise, 
economical, robust and rapid UV spectrophotometric method and validated for quantification 
of naratriptan. The influence of three different solvents on estimation of naratriptan from bulk 
and pharmaceutical dosage forms was studied. The solutions of naratriptan were prepared 
with the water and the solvent blends containing water: acetonitrile (1:1) and water: methanol 
(1:1). The solutions were scanned within the ranges of 200 nm to 400nm. Naratriptan 
exhibited λmax at 283.5 nm in case water. However the λmax was slightly shifted to 285 nm 
in case of acetonitrile: water and 284.5 in methanol: water. The method obeyed Beer-
Lamberts law within the range of 10 to 50 µg/ml concentration.  
 
Vishwanathan. K. et. al [23]., developed a rapid, sensitive and selective method for the 
determination of antimigraine drugs from human serum to study pharmacokinetics of these 
drugs administered concurrently. Solid phase extraction (SPE) using Oasis HLB was used to 
extract the drugs (sumatriptan, naratriptan, zolmitriptan and rizatriptan) and the internal 
standard bufotenine from serum. A method based on liquid chromatography/tandem mass 
spectrometry (LC/MS/MS) was developed and validated to simultaneously quantitate these 
antimigraine drugs from human serum. The precursor and major product ions of the analytes 
were monitored on a triple quadrupole mass spectrometer with positive ion electrospray 
ionization (ESI) in the multiple reaction monitoring (MRM) mode.  
Ramesh. C. et. al [24]., reported a three simple sensitive and reproducible visible 
spectrophotometric methods (A, B, and C) for the determination of naratriptan hydrochloride 
(NTP) in samples and pharmaceutical formulations. Method A was based on the formation of 
colored co-ordination complex with cobalt thiocyanate (CTC). Method B was based on the 
formation of colored species with citric acid - acetic anhydride (CiA-Ac O). Method C was 
based on the formation of colored molecular complex involving NTP and sodium nitroprusside 
(SNP) in the presence of hydroxylamine mono hydrochloride (HA). Regression analysis of Beer’s 
law plots showed good concentration ranges 5-35, 2-10 and 10-60 µg/ml for methods A, B 
and C  respectively. The applicability of the methods was examined by analyzing tablets of  
NTP. 
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AIM AND PLAN OF THE STUDY 
 AIM AND SCOPE: 
Naratriptan Hcl is a new drug, used in the treatment of migraine headaches. From the 
literature survey, it was found that there are very few RP-HPLC methods available for the 
quantification of naratriptan Hcl in tablet formulation. Early workers have also reported the 
determination of the drug by hyphenated techniques such as LC-MS and also by UV 
spectrophotometry. 
Hence the aim of present work is to develop simple and validated RP-HPLC method 
by isocratic mode for the quantification of naratriptan Hcl in tablet formulation. 
PLAN OF WORK: 
The plan of present work is as follows: 
Method Development 
¾ Selection of wavelength  
¾ Selection of initial separation conditions   
¾ Selection of mobile phase (pH, peak modifier, solvent strength and 
flow rate) 
¾ Nature of the stationary phase 
¾ Selection of separation method  
 
Validation of the developed method 
            The developed method was validated by using the various validation 
parameters such as,  
¾ Accuracy 
¾ Precision 
¾ Linearity, limit of detection (LOD) and limit of quantitation (LOQ) 
¾ Selectivity / Specificity 
¾ Robustness / ruggedness 
¾ System suitability. 
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  METHODOLOGY 
        1) MATERIALS AND INSTRUMENTS USED: 
    a) Chemicals and Solvents used: 
S.No Name Grade 
1. Water Millipore 
2. Acetonitrile  Merck (HPLC Grade) 
3. Potassium di hydrogen 
phosphate 
 AR grade 
4. Orthophosphoric acid   AR grade 
 
           b) Apparatus/ Instruments used: 
S.No Name Model 
1 HPLC  
     Pump Waters  E 2695 
    Uv visible detector Waters 2489  
    Column C18 
[250mmX 4.6mm,5µ] 
Phen-s 
2 Electronic balance Mettle Toledo 
3 pH meter Elico 
4 Sonicator  Sonorex dig 10 p 
5 Membrane filter AXIVA,SRP 15, 
0.45 micron 
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2) ANALYTICAL METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITION 
I. Determination of wave length: 
                 A standard solution of the drug was prepared in water as follows in the 
following manner. A bout100 mg of naratriptan hydrochloride (Pure drug) was weighed 
accurately and dissolved in 100 ml of distilled water.  From this 1ml was taken and 
made up to the final volume with water 10 ml in a volumetric flask so as to obtain the 
conc. of 100 µg/ml. 
                The resulting solution was scanned in the range of 200 nm to 400 nm in a 
UV-Vis spectrophotometer. The spectrum exhibited λmax at 224 nm and 280 nm. As the 
absorption was high at 224 nm, this wavelength was selected for the chromatographic 
method development. The data for the UV absorption spectrum was shown in table no.2 
and the spectrum was shown in fig.1. 
Table -2 
 Data for UV absorption spectrum 
S. No. Wavelength in nm Absorbance 
1. 200 0.765 
2. 205 0.842 
3. 210 0.856 
4. 215 0.934 
5. 224 1.020 
6. 230 0.756 
7 250 0.695 
8 260 0.535 
9 270 0.576 
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10 280 0.685 
11 290 0.604 
12 300 0.534 
13 310 0.412 
14 320 0.326 
15 330 0.205 
16 340 0.194 
17 350 0.185 
 
 
Fig 1: UV spectrum of naratriptan Hcl 
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II. Optimization of chromatographic parameters: 
a. selection of mode of separation. 
                As the drug was polar in nature, RP-HPLC method was preferred. 
b. Selection and standardization of mobile phase and column: 
        The method development of naratriptan Hcl required adequate resolution of the 
drug peak in the chromatogram. To obtain a resolved peak, several solvent systems and 
different columns were tried and finally spursil C18 column with Acetonitrile and 
phosphate buffer (30:70) as mobile phase were selected for the analysis. 
III. Preparation of Mobile Phase:  
  Preparation of buffer: 
                 About 1.368 gm of potassium di hydrogen phosphate was accurately weighed 
and transferred in to a 1 lit beaker. The salt was dissolved in water and diluted to 1 lit 
with water. The pH was adjusted to 7.2 with ortho phosphoric acid  
Preparation of mobile phase: 
                 A mixture of acetonitrile and buffer solution (30:70) was prepared, mixed 
well and filtered through 0.45 µ membrane filter and degassed.  
IV. Selection of flow rate: 
             Different flow rates were tried in the method development for the drug. The 
peak shapes of drug showed fronting and tailing with the flow rate 0.6ml and 0.8ml/min 
respectively. Finally the flow rate with 1.0 ml per minute was selected for the analysis. 
V. Determination of Retention time: 
 Standard stock solution of naratriptan Hcl:  
                 About 10 mg of naratriptan Hcl working standard was accurately weighed 
and transferred in to a 50 ml volumetric flask, about 25 ml of water was added; 
sonicated to dissolve it completely and made up the volume up to the mark with the 
same solvent (Stock solution 200 µg/ml) 
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Preparation of standard solution of naratriptan Hcl:     
              Further 5 ml of the above stock solution was pipetted into a 10 ml volumetric 
flask, diluted up to the mark with water. The solution was mixed well and filtered 
through 0.45 µ membrane filter. 
              10 µl of the solution was injected in to the chromatographic system and the 
chromatogram was recorded. The retention time of naratriptan Hcl was found to be at 
3.285 min. The chromatogram was shown in fig. 6 
The experiment was repeated under different set of condition (trial 1 to trial 4) 
and shown as follows.  
Trail 1:   
Chromatographic conditions  
Stationary phase        : Spursil C18, 5 micron particle size, 250mm × 4.6mm         
Mobile phase                  :  Acetonitrile: methanol: Phosphate buffer (60:25:15)                            
Detection                 :  224 nm 
            Flow rate                         :  0.6 ml/min 
  Run time                   :  5.8 min 
Sample size      :  10 μl 
Needle wash                 :  Water HPLC grade  
Column temperature       :  Ambient  
 
 
 
 
 
 
Chapter-V                                                                                                                          Methodology                            
 
PHARMACEUTICAL ANALYSIS, K. M. C. P.  Page 39 
 
                                       Chromatogram for trail condition-1 
 
   Fig: 2  
  Observation:  Peak shape was not good and asymmetry was more than the limit. 
 
 
Trail-2 
Chromatographic conditions  
                     Stationary phase        : Spursil C18, 5 micron particle size, 250mm × 4.6mm 
       Mobile phase             :  Acetonitrile: Phosphate buffer (55:45) 
          Detection         :  224 nm 
           Flow rate                   :  0.8 ml/min 
           Run time           :  6 min 
          Sample size         : 10 μl 
          Needle wash         : Water HPLC grade  
        Column temperature   : Ambient 
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                                      Chromatogram for trail condition-2 
 
Fig: 3 
Observation: Peak shape was not good, theoretical plates were too less and asymmetry 
was more than the limit. 
 
 
Trail-3 
Chromatographic conditions  
                    Stationary phase        : Spursil C18, 5 micron particle size, 250mm × 4.6mm 
      Mobile phase             :  Acetonitrile: Phosphate buffer (50:50) 
         Detection         :  224 nm 
          Flow rate                    :  1 ml/min 
          Run time           :  5 min 
         Sample size         : 10 μl 
         Needle wash         : Water HPLC grade  
        Column temperature   : Ambient 
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                        Chromatogram for trail condition-3 
 
Fig: 4 
 Observation:  Peak shape was not good; asymmetry was more than the limit. 
 
Trail-4 
Chromatographic conditions  
                    Stationary phase         : Spursil C18, 5 micron particle size, 250mm × 4.6mm 
      Mobile phase             :  Acetonitrile: Phosphate buffer (40:60) 
         Detection         :  224 nm 
          Flow rate                    :  1 ml/min 
          Run time           :  5.4 min 
         Sample size         : 10 μl 
         Needle wash         : Water HPLC grade  
        Column temperature   : Ambient 
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                     Chromatogram for trail condition-4 
        
 
 Fig-5 
Observation: Peak shape was good, theoretical plates were too less and asymmetry 
was more than the limit. 
 
 OPTIMIZED METHOD 
  FIXED CHROMATOGRAPHIC CONDITION 
         Stationary phase             : Spursil C18, 5 micron particle size, 250mm × 4.6mm 
         Mobile phase                 :  Acetonitrile: Phosphate buffer (30:70) 
         Flow rate  : 1.0 ml/ min 
        Wavelength  : 224 nm 
         Injection volume : 10 μl 
         Needle wash             : Water HPLC grade  
        Column temperature : Ambient 
         Run time   : 5 min.    
 
Chapter-V                                                                                                                          Methodology                            
 
PHARMACEUTICAL ANALYSIS, K. M. C. P.  Page 43 
 
                          Chromatogram for fixed Chromatographic Condition 
Fig6:  
Observation: Peak shape was good, theoretical plates were adequate and asymmetry 
was within the limit. 
QUANTITATIVE DETERMINATION OF THE DRUG BY USING THE 
DEVELOPED METHOD 
Sample        :    Naratriptan Hcl tablet 
Label claim:    1 mg 
Preparation of blank: Millipore water was used as blank. 
Standard solution of naratriptan Hcl:       
               About 10 mg of naratriptan Hcl working standard was accurately weighed and 
transferred in to 50 ml volumetric flask, added about 25 ml of water and sonicated to 
dissolve it completely and made up the volume up to the mark with the same solvent 
(Stock  solution 200 µg/ml ) 
                      Further 5 ml of the above stock solution was pipetted into a 10ml 
volumetric flask, diluted up to the mark with water, mixed well and filtered through 
0.45µm filter. (The final concentration of resulting solution was 100 µg/ml). 
Sample solution of naratriptan Hcl:  
             20 naratriptan Hcl tablets were weighed and calculated the average weight.  The 
sample equivalent to 10 mg of naratriptan Hcl was accurately weighed and transferred 
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in to 50 ml volumetric flask added, about 25 ml of water and sonicated to dissolve it 
completely and made up the volume up to the mark with diluent, mixed well and 
filtered through 0.45µm filter. 
 Further 5 ml of the above stock solution was pipetted into a 10 ml volumetric 
flask. The volume was made up with the diluent, mixed well and filtered through 
0.45µm filter. (The final concentration of resulting solution was 100 µg/ml). 
Procedure:            
                 10 µl of the solution of each of blank, standard and sample solution were 
injected separately in to the chromatographic system. The chromatograms were 
recorded, shown in fig.7-9 and reported in table.3. 
 
Amount of drug present in the tablet was calculated using the following formula: 
Content of the drug in a tablet of average weight 
 
     
   =   ୗୟ୫୮୪ୣ ୟ୰ୣୟ
ୱ୲ୟ୬ୢୟ୰ୢ ୟ୰ୣୟ
 ×ୱ୲ୟ୬ୢୟ୰ୢୢ୧୪୳୲୧୭୬
ୱୟ୫୮୪ୣ ୢ୧୪୳୲୭୬
× ୮୭୲ୣ୬ୡ୷
ଵ଴଴
 × Average weight of tablet 
 
                                                                 
        
 
 
            Percentage content =  
୅୫୭୳୬୲ ୮୰ୣୱୣ୬୲
୐ୟୠୣ୪ ୡ୪ୟ୧୫
 × 100 
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Chromatogram of Blank  
 Fig.7 
           
           
 
 
 Chromatogram of Standard preparation  
 
           Fig.8 
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Chromatogram of assay preparation 
 
Fig.9
 
 
      
 
 
 
 
 
Table-3 
Data for assay 
 
. 
 SI. no 
 
 
 content 
 
Label  
Claim(mg)
 
       Peak area 
 
 Amount 
Present(mg) 
 
 
Percent  
Content standard sample 
    
     1. 
 
  
Naratriptan 
 
  1mg 
 
7219001 
 
7142112
 
      0.989 
 
   98.93% 
 
 
 
    Acceptance criteria:  97.0- 103% w/v. 
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VALIDATION 
Validation of analytical method for assay of naratriptan Hcl: 
Validation of analytical method is a process to establish that the performance 
characteristics of the developed method meet the requirement of the intended analytical 
application. 
Design of experiment:  
   Typical analytical parameters used in assay validation were, 
• Accuracy 
• Precision 
• Linearity and range 
• Limit of  Detection(LOD) 
•       Limit of Quantitation(LOQ) 
•       Specificity 
•       Robustness 
•       Ruggedness 
•       System suitability  studies 
‐ Theoretical plate count 
‐ Relative standard deviation 
‐ The tailing factor 
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1. ACCURACY 
              The accuracy of an analytical method is the closeness of the test result obtained 
by that method to the true value. 
               Accuracy is measured as the percentage of the analytes recovered by the 
assay. Spiked samples were prepared in triplicate at three intervals a range of 50-150% 
of the target concentration and injected in to the HPLC system. 
Acceptance criteria  : percentage recovery should be with in 97-
103%  w/v 
 
Preparation of working mixture solution: 
              Naratriptan working standard equivalent to 50%, 100%, 150% were weighed 
accurately and transferred in to three different 50 ml volumetric flask. 200 mg of 
placebo was weighed and transferred to each flask, dissolved with small volume of 
diluent and made up the volume. 5 ml of this solution was diluted to 10 ml with water. 
The solution was filtered through 0.45 µ membrane filter.  
             10 µl of each of this solution were injected and chromatograms were recorded 
as shown in fig. 10-12. The recovery study data for naratriptan was shown in table 4.   
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter-VI                                                                       Method validation    
 
PHARMACEUTICAL ANALYSIS, K. M. C. P.  Page 49 
 
Chromatogram for accuracy at 50% 
 Fig.10
 
 
  
 
Chromatogram for accuracy at 100 % 
 Fig.11 
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Chromatogram for accuracy at 150%  
  Fig.12           
 
 
Data for accuracy studies 
Table-4 
 
 
 
SI. 
No. Recovery 
Area 
obtained 
Average 
area 
Amount 
added in 
mg 
 
Amount 
recovered 
in mg 
% Recovery 
 
1 
 
 
50% 
 
 
3474789 
 
3506014 
 
 
5.010 
 
 
4.897 
 
 
97.94% 
 
3558456 
3484798 
2 
 
100% 
 
 
7134565 
7202001 
 
 
10.021 
 
9.956 
 
99.56% 
 7125469 
7345969 
 
3 
 
 
150% 
 
10089721 
 
10693349
 
 
15.022 
 
 
14.783 
 
 
98.55% 
 
11092674 
10897654 
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2. PRECISION 
         Precision of an analytical method is the degree of agreement among individual 
test result when the procedure is applied repeatedly to multiple sampling of a 
homogenous sample. Precision of analytical method is usually expressed as the standard 
deviation or relative standard deviation. 
Determination: 
         The precision of the analytical method is determined by assaying the samples 
consecutively number of times and relative standard deviation was calculated.  
Acceptance 
criteria 
: The relative standard deviation should be  with in 2% 
   
a) System precision: 
 Preparation of standard solution: 
                10 mg of naratriptan Hcl working standard was accurately weighed and 
transferred into a 50 ml volumetric flask added then about 25 ml of water, sonicated to 
dissolve it completely and made up the volume up to the mark with the same solvent 
(Stock  solution was 200 µg/ml). 
                  Further 5 ml of the above stock solution was pipetted into a 10 ml volumetric 
flask, diluted up to the mark with water. Mixed well and filtered through 0.45 µ 
membrane filter. (The final concentration of resulting solution was 100 µg/ml). 
Method: 
                The system precision was evaluated by measuring the peak response of 
naratriptan for six replicate injections of the standard solution and chromatogram were 
recorded and shown in fig.13 and precision data of system was shown in table 5. 
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The standard deviation and relative standard deviation were calculated from the 
statistical formula 
Standard deviation (σ)     = 1
)( 2
−
−∑
n
xx
  
                      x = sample value 
                     x  = mean value of sample 
                      n = number of sample 
                                              Relative standard deviation = 100x
x
σ
 
 
 
System precision 
Chromatogram of standard  
Fig.13 
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               Data for system precision 
Table -5 
 
 
 
 
 
 
 
 
 
 
b) Method precision: 
                        20 naratriptan Hcl tablets were weighed and calculated the average 
weight.  The sample equivalent to 10 mg of naratriptan Hcl was accurately weighed and 
transferred into a 50 ml volumetric flask then added about 25 ml of water about 
sonicated to dissolve it completely and made up the volume up to the mark with same 
solvent. The solution was mixed well and filtered through 0.45µ membrane filter. 
 Further 5 ml of the above sample solution was pipetted into a 10 ml volumetric 
flask, diluted up to the mark with diluent. Mixed well and filtered through 0.45µ 
membrane filter. 
Procedure:  
The method precision (repeatability) was determined by preparing the sample of 
single batch of naratriptan tablet formulation for six times and six successive injection 
of 10 lμ of working sample solution were injected and the chromatograms were 
No. of injection Peak area 
Injection-1 7352659 
Injection-2 7124565 
Injection-3 7149579 
Injection-4 7352659 
Injection-5 7124565 
Injection-6 7149579 
Average 7208934.3 
Standard Deviation 111889 
%RSD 1.55 
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recorded and shown in fig.14 and method precision (repeatability) data of naratriptan 
was shown in table 6. 
Method precision  
Chromatogram for method precision 
Fig.14                 
     Data for method precision 
Table-6 
SI.No 
Tablet  powder 
Weight in mg 
Peak Area 
obtained 
Assay value 
in mg 
% Label claim w/v 
1 
2 
3 
4 
5 
6 
2040 
2039 
2041 
2038 
2042 
2043 
7149579 
7124565 
7352659 
7149579 
7124565 
7352659 
0.990 
0.987 
1.018 
0.991 
0.985 
0.997 
99.03 
98.74 
101.80 
99.13 
99.59 
99.71 
 Mean 99.48 
 Standard deviation 1.205 
 % Relative standard deviation 1.21 
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3. LINEARITY AND RANGE 
       Linearity was assessed by performing measurement at several analyte 
concentrations. Minimum five concentrations were recommended for linearity studies. 
       The linearity of an analytical method is its ability to elicit test results that is directly 
proportional to the concentration of analyte in sample with in a given range. The 
linearity of an analytical method is determined by mathematical treatment of test result 
obtained by analysis of samples with analyte concentration across claimed range of 
peak area Vs concentration is plotted and percentage curve fitting is calculated. 
Acceptance criteria  : Correlation coefficient should not be less 
than 0.99%. 
Percentage curve fitting should not be less 
than 99.7%. 
 
Method: 
Preparation of working standard solution: 
                Naratriptan equivalent to 50%, 75%, 100%, 125% and 150% level were 
weighed accurately and taken in different 50 ml volumetric flask, dissolved in the 
diluent and the volume were made up with diluent to obtain the concentration of 50, 75, 
100, 125, 150 µg/ml.  
               10 µl of each of working standard solutions were injected separately and the 
chromatogram were recorded and shown in fig.15-19. 
              The correlation coefficient and percentage curve fitting were calculated from 
the following formula, 
                         R =   ଷ൫௑ି௑൯
మ
 ൫௒ି௒൯
మ
  
ሺ௡ିଵሻ ௌೣ ௌ೤
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                        Where, 
                                           X = concentration, 
                                           Y = instrumental response, 
                                           Sx = Std.Deviation of x  
                                           Sy = Std.Devitation of y 
             Percentage curve fitting = 100×correlation coefficient 
The linearity data and analytical performance parameters of naratriptan was shown in 
table.7-8 and calibration curve of naratriptan was shown in fig.20 
 
 
Chromatogram for linearity level at 50%  
Fig.15
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Chromatogram for linearity level at 75%  
Fig.16 
 
 
 
Chromatogram for linearity level at 100%  
Fig.17 
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Chromatogram for linearity level at 125%  
Fig.18  
     
 
 
 
Chromatogram for linearity level at 150%  
Fig.19 
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CALIBRATION CURVE OF NARATRIPTAN 
 Fig.20 
 
                 
 
                              Data for Linearity  
Table - 7 
             
 
 
    
y = 72029x
R² = 0.999
0
2000000
4000000
6000000
8000000
10000000
12000000
0 50 100 150 200
Pe
ak
 a
re
a
Concentration in µg/ml
Series1
Linear (Series1)
SI.
No 
Concentration of 
naratriptan Hcl    
µg/ml 
Average peak 
area 
1 50µg/ml 3574789 
2 75µg/ml 5362183 
3 100µg/ml 7449578 
4 125µg/ml 8936972 
5 150 µg/ml 107243647 
Correlation Coefficient 0.999 
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ANALYTICAL PERFORMANCE OF NARATRIPTAN HCL 
Table-8 
          
 
 
 
 
 
 
 
Acceptance criteria: The relationship between the concentration and response of 
naratriptan Hcl should be linear in the specified range and the regression coefficient 
should not be less than 0.999.                                             
                                 
 
 
 
 
 
 
 
 
 
Parameters Values 
Linear dynamic range  50 -150 µg/ml 
Correlation Coefficient 0.999 
Percentage curve fitting of slope 99.9% 
Slope 7449578 
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4. LIMIT OF DETECTION (LOD) 
       It is the lowest amount of analyte in a sample that can be detected but not 
necessarily quantities as an exact value under the stated experimental condition. The 
detection limit is usually expressed as the concentration of analyte (e.g. parts per 
million). 
        It is determined by based on the standard deviation of response and the slope the 
detection limit may be expressed as 
LOD = 3.3 σ /S 
                          Where, 
                                   σ     =  The standard deviation of the response  
                                   S     =  The slope of the calibration curve  ( of the analyte) 
 
 
From the formula the limit of detection was found to be  
           
       LOD 
 
Naratriptan Hcl 
0.04956 µg/ml 
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5. LIMIT OF QUANTITATION 
The quantitation limit of an analytical procedure is the lowest amount of analytical 
procedure is the lowest amount of analyte in a sample, which can be quantitated with 
suitable precision and accuracy. Based on the deviation of the response and the slope. 
 Quantitation limit (QL) may be expressed as 
                                                        LOQ = 10 σ /S 
                      Where, 
                                   σ     =  The standard deviation of the response  
                                   S     =  The slope of the calibration curve  ( of the analyte) 
 
From the formula the limit of detection was found to be 
 
          LOQ 
Naratriptan Hcl 
0.1502 µg/ml 
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6. SPECIFICITY 
             The specificity of the method was evaluated by analyzing the sample solution 
spiked with the excipients at appropriate levels. The assay result was unaffected by the 
presence of extraneous materials. 
Determination: 
The specificity of the analytical method was determined by injecting the placebo 
solution under the same experimental conditions as that of assay. 
Preparation of placebo: 
Placebo was prepared by mixing all the excipients without active ingredients. 
Procedure: 
             200 mg of placebo was accurately weighed and transferred in to a 50 ml 
volumetric flask then added about 25 ml of water and sonicated to distribute content for 
5 minutes. The volume was made up with same solvent. The solution was filtered 
through whatman filter paper. 
             Further 5ml of above solution was pipetted into 10 ml of volumetric flask 
diluted up to the mark with water. The solution was filtered through 0.45µ membrane 
filter. 
Standard solution of naratriptan Hcl:                
             10 mg of naratriptan Hcl working standard was accurately weighed and 
transferred into a 50 ml volumetric flask then added about 25 ml of water, sonicated to 
dissolve it completely and made up the volume up to the mark with the same solvent 
(Stock  solution 200 µg/ml)                       
              Further 5 ml of the above stock solution was pipetted into a 10 ml volumetric 
flask diluted up to the mark with water. Mixed well and filtered through 0.45µ 
membrane filter. (The final concentration of resulting solution was 100 µg/ml). 
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Naratriptan standard+ placebo 
         200 mg of placebo and standard solution equivalent to 1mg of naratriptan Hcl 
were transferred in to 50 ml volumetric flask then added about 25 ml of water, 
sonicated to dissolve it content for 5 minutes. The volume was made up with water. The 
solution was filtered through 0.45µ membrane filter. 
         Further 5 ml of above solution was pipetted in to a 10 ml of volumetric flask 
diluted up to the mark with water. The solution was filtered through 0.45µ membrane 
filter. 
         10 µl 0f the solution of each of placebo, standard and standard+placebo solution 
were injected separately in to the chromatographic system. The chromatograms were 
shown in fig.21-23 and reported in table.9. 
 
SPECIFICITY 
Chromatogram for placebo preparation 
Fig.21     
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Chromatogram for standard preparation: 
           Fig.22 
             
       
 
 
 
Chromatogram for Standard + placebo preparation 
 Fig.23 
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 Data of specificity 
Table -9 
 
 
SI.No 
 
Sample 
 
Area obtained 
 
Percent content of 
Drug 
 
 
1. 
 
          Standard 
 
         7219001 
 
             98 
 
2. 
 
Standard+ Placebo 
 
7124565 
 
98.7 
3. Placebo 0 0 
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7. ROBUSTNESS 
       Robustness of an analytical method is measure of its capacity to remain unaffected 
by small but deliberate variation in method parameters and provides an indication of its 
reliability during normal usage. 
Determination: 
       The robustness of an analytical method was determined by analysis of aliquots 
from homogenous lots by differing physical parameters that may differ but were still 
within the specified parameters of the assay such as change in physical parameters like 
flow rate and column temperature. 
Method 
Preparation of Standard solution:        
               10 mg of naratriptan Hcl working standard was accurately weighed and 
transferred in to a 50 ml volumetric flask then added about 25 ml of water and sonicated 
to dissolve it completely and made up the volume up to the mark with the same 
solvent(Stock  solution 200 µg/ml).  
              Further 5 ml of the above stock solution was pipetted in to a 10 ml volumetric 
flask, diluted up to the mark with water. Mixed well and filtered through 0.45µ 
membrane filter. (The final concentration of resulting solution was 100  µg/ml).               
Procedure: 
a) The flow rate was varied at 0.8 to 1.2 ml/min. 
          Standard solution 100 µg/ml was prepared and analysed using the varied flow 
rates. On evaluation of the above results, it can be concluded that the variation in flow 
rate do not affect the method significantly. Hence it indicates that the method is robust 
up on the change in the flow rate ±0.2 ml/min. 
b) The temperature was varied at 28 0C to 32 0C. 
           Standard solution 100 µg/ml was prepared and analysed using the varied 
temperature. On evaluation of the above results, it can be concluded that the variation 
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in temperature do not affect the method significantly. Hence it indicates that the 
method is robust even after the change in the column temperature ±2 0C. 
Procedure: 
         10 µl of various working standard solution was injected and chromatogram was 
recorded and shown in fig.24-29 and results are shown in table.10-13. 
CHROMATOGRAM FOR ROBUSTNESS  
a) Effect of change in flow rate (0.8 ml/min) 
 Fig.24
 b) Effect of change in flow rate (1.0 ml/min) 
  Fig.25  
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c) Effect of change in flow rate (1.2 ml/min) 
Fig.26
 
          
          
Report of robustness (change in flow rate 0.8 ml/min) 
Table -10 
        
 
 
 
 
 
             
 
 
 
 
Drug 
Average 
area (flow 
rate  0.8 
ml/min) 
Average 
area (flow 
rate 1.0 
ml/min) 
Standard 
deviation % RSD 
Naratriptan 
Hcl 
7413428 7219001 23223 0.31 
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Report of robustness (change in flow rate 1.2 ml/min) 
Table -11 
       
 
 
 
 
 
             Acceptance criteria: The percentage RSD should be not more than 2.0 
 
CHROMATOGRAM FOR ROBUSTNESS 
 a) Effect of change in column temperature (28 0C) 
 Fig.27 
 
  
 
 
Drug 
Average area 
(flow rate 
1.2.ml/min) 
Average 
area (flow 
rate  1.0 
ml/min) 
Standard 
deviation 
% RSD 
Naratriptan 
Hcl 
7012141 7219001 69649 0.98 
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 b) Effect of change in column temperature (30 0C) 
 Fig.28
 
c) Effect of change in column temperature (32 0C) 
Fig.29 
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Report of robustness (change in column temperature 28Ԩ) 
Table -12 
       
 
 
 
 
   
Report of robustness (change in column temperature 32Ԩ) 
Table -13 
       
 
 
 
 
 
 
 
            Acceptance criteria: The percentage RSD should not be more than 2.0 
 
 
 
 
 
 
Drug 
Average area 
(column 
temperature 
28 Ԩ) 
Average area 
(column 
temperature 
30 Ԩ) 
Standard 
deviation % RSD 
Naratriptan  
Hcl 
7093821 7219001 44293 0.62 % 
Drug 
Average area 
(column 
temperature 
32 Ԩ) 
Average area 
(column 
temperature 
30 Ԩ) 
Standard 
deviation % RSD 
Naratriptan  
Hcl 
7123740 7219001 98461 1.34 % 
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8. RUGGEDNESS 
The ruggedness of an analytical method is degree of reproducibility of test result 
obtained by the analyst under a variety of normal test condition such as different 
laboratories different analysts different instruments, different lots of reagents different 
elapsed assay times, different temperature, different days etc. 
            The ruggedness of an analytical method was determined by aliquots from 
homogenous lots by different analyst using operational and environmental conditions 
that may differ but are also with in the specified parameters of the assay. The degree of 
reproducibility of test results is then determined as function of the assay variables. This 
reproducibility may be compared with the precision of the assay under normal condition 
to obtain a measure of the ruggedness of the analytical method. The assay of naratriptan 
was performed in different days. 
Method: 
         Working standard solution and working sample solution of naratriptan were 
prepared by different analyst and on different days and 10 µl of working standard 
solution and working sample solution were injected. The chromatograms were recorded 
and shown in fig.30-37 and ruggedness of the method were reported in table.14.  
  
Acceptance criteria: 
a) The relative standard deviation for the assay values of five sample preparations 
of same batch should not be more than 2.0%. 
b) The difference in the assay of same batch of naratriptan Hcl between two 
analysts should not be more than 2.0%. 
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RUGGEDNESS FOR ANALYST-I 
Chromatogram for standard preparation 
Fig.30 
         
 
    
    
Chromatogram for sample preparation 
Fig.31 
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     RUGGEDNESS FOR ANALYST-II 
Chromatogram for standard preparation 
Fig.32 
    
 
 
 
 
 
Chromatogram for Sample preparation 
Fig.33 
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RUGGEDNESS FOR INSTRUMENT-I AND ANALYST-III 
Chromatogram for standard preparation 
Fig.34 
 
Chromatogram for sample preparation 
Fig.35 
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RUGGEDNESS FOR INSTRUMENT-II AND ANALYST-IV 
Chromatogram for standard preparation 
 Fig.36 
     
 
 
Chromatogram for sample preparation: 
Fig.37 
 
 
 
 
 
Chapter-VI                                                                       Method validation    
 
PHARMACEUTICAL ANALYSIS, K. M. C. P.  Page 78 
 
               Data for ruggedness 
Table-14 
                 
 
 
 
  
 
  
 
 
 
 
 
Acceptance criteria: The percentage RSD should not be more than 2.0 
 
 
 
 
 
 
 
 
 
 
SI.no 
 
 
Instrument 
code 
 
Analyst Date of      analysis 
Percentage 
content 
 
1 
 
Waters-2695 
 
I 21-11-2011 
 
98.27% 
 
2 
 
Waters-2695 
 
II 22-11-2011 
 
98.12% 
 
3 
 
Waters-2695 
 
III 
   
 23-11-2011 
 
98.33% 
 
4 
 
 Peak 7000 IV 
 
 24-11-2011 
 
98.74% 
  
Mean 
 
98.36% 
  
Standard deviation 
 
0.2695 
  
% Relative standard deviation 
 
0.27 
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9. SYSTEM SUITABILITY PARAMETERS 
The system suitability studies were carried out as specified in USP. These parameters 
include % RSD for peak area, tailing factor and theoretical plates. 
Determination 
          To determine the suitability of chromatographic system described for the method 
of analysis by establishing system suitability parameters like peak tailing factor, number 
of theoretical plates and the %RSD of naratriptan standard preparation on daily basis. 
Method 
Preparation of Standard solution:                      
                 10 mg of naratriptan Hcl working standard was accurately weighed and 
transferred in to a 50 ml volumetric flask then added about 25 ml of water and sonicated 
to dissolve it completely and made up the volume up to the mark with the same solvent 
(Stock  solution 200 µg/ml) .                     
              Further 5 ml of the above stock solution was pipetted in to a 10 ml volumetric 
flask, diluted up to the mark with water. Mixed well and filtered through 0.45µ 
membrane filter. (The final concentration of resulting solution was 100 µg/ml). 
Acceptance criteria: 
a. The column efficiency is not less than 2000 theoretical plates. 
b. The tailing factor for the analyte peak is not more than 2.0. 
c. The relative standard deviation for the replicate injections is not more than 
2.0%. 
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Chromatogram for system suitability parameters 
Fig.38 
 
                               
 
 
 
 
                  Data for System Suitability Parameters 
         Table-15 
      
           
 
System suitability factors Results Limit 
 %RSD 1.55 NMT 2% 
 Tailing factor 1.01 NMT 2 
Number of Theoretical plates 6839 NLT 2000 
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RESULTS AND DISCUSSION 
           There is no official method for the estimation of naratriptan Hcl in any 
pharmacopoeia. Naratriptan is increasingly used in the treatment of migraine headaches. 
Hence it was felt necessary to develop a sensitive method for the estimation of naratriptan 
Hcl. 
                The method was developed with mobile phase system of potassium di hydrogen 
phosphate buffer pH 7.2 and acetonitrile in the ratio (7:3) v/v with flow rate 1.0 ml/min on 
spursil C18, 250 X 4.6 mm, 5 µm particle size with UV detection at 224 nm gave a 
satisfactory chromatogram with naratriptan of retention time 3.285 min. It was shown in 
fig.6. 
           The present proposed system provides shorter analysis time and conserves mobile 
phase system. The method was validated based on United States pharmacopoeia and ICH 
parameters. The parameters are accuracy, precision, linearity, specificity, LOD, LOQ, 
ruggedness and robustness. 
                 The specificity of the method was found by injecting the placebo and placebo 
spiked with standard and observed that there was no interference due to placebo. These 
chromatograms were shown in fig. 21-23 and data were reported in table 9. 
                The data regarding the linearity is given in table 7-8 and calibration graph were 
represented in fig.20 and chromatograms were shown in fig.15-19. From the linearity studies, 
the specified range was determined for the drug. 50-150 µg/ml of naratriptan and linearity co-
efficient and percentage curve fitting was found to be 0.999 and 99.9% respectively for 
naratriptan. 
                 The precision of the method was determined by replicate injections of sample 
solution. The percentage of RSD of assay was found to be in 1.21 for naratriptan which was 
with in the range of acceptance criteria of 2%. Thus the proposed method was found to be 
providing high degree of precision and reproducibility. The chromatograms are shown in 
fig.14 and data are reported in table 6. The precision of the system was determined by 
multiple injections of a set of solution of same concentration of naratriptan. The instrument 
response was found to be reproducible as found from % RSD of 1.55 of naratriptan that was 
Chapter VII                                                                                                                   Results and discussion 
 
PHARMACEUTICAL ANALYSIS, K. M. C. P.   Page 82 
 
well with in the acceptance criteria of 2% the chromatograms are shown in fig.13 and data 
are reported in table 5. 
                                          
                The validation of the proposed reverse phase HPLC method was further verified by 
recovery studies. The percentage recovery was found to be with in 97-103% w/v of 
naratriptan. This serve a good index of accuracy and reproducibility of the proposed method 
and fig was shown in 10-12 and data were reported in table 4. 
                The limit of detection and limit of quantitation of the drugs were calculated and 
found to be 0.04956 and 0.1502 mcg per ml 
                 Robustness was determined by carrying out the assay during which the flow rate 
ratio and column temperature was altered slightly. The % RSD when flow rate was altered to 
0.8 ml was found to be 0.31% and % RSD when flow rate was altered to 1.2 ml was found 
0.98% and 0.62 %, 1.34% was obtained on slight variation in the temperature ratio, indicated 
that the method is robust and does not show variation in the results on slight variation in flow 
rate ratio and temperature also give % RSD with in acceptance criteria and chromatograms 
were shown in fig.24-29 and data were reported in table.10-13 indicating lack of influence on 
the test results by operational variable for the proposed method 
                The ruggedness of the method was determined by performing the same assay by 
different analyst, on different day to check the reproducibility. The test results were found to 
be 98.27%, 98.12% for naratriptan when the analysis was carried out by two different 
analysts on two different days. The ruggedness of the method was also determined by 
performing the assay by different analysts on different instrument and results were found to 
be 98.33%, 98.74% for naratriptan. Thus the result were found to be highly reproducible in 
spite of variation in the condition which could be normally expected from analyst to analyst 
and analysis carried out on different days and the chromatograms are shown in fig.30-37 and 
data were reported table 14. 
   The system suitability parameters were calculated to ascertain the suitability of the 
proposed method on the given system on C18 column and mobile phase of potassium di 
hydrogen phosphate buffer pH7.2 and acetonitrile (7:3). The number of theoretical plates was 
found to be 6839 for naratriptan. The tailing factor for naratriptan was 1.01. The 
chromatograms were shown in fig 38.                
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CONCLUSION 
As the literature survey reveals that there are very few method have been reported for the 
determination of the naratriptan Hcl and so a modified RP-HPLC method was developed for 
the estimation of drug in tablet dosage form and validated. 
                    HPLC waters ALLIANCE 2695 with column spursil C18, 250 X 4.6 mm, 5 µ 
AGILENT was used. A volume of 10 µl of drug solution was injected and eluted with the 
mobile phase of potassium di hydrogen phosphate buffer pH 7.2: acetonitrile in the ratio of 
7:3 v/v, which was pumped at the flow rate of 1.0 ml and detected by UV detector at 224 nm. 
The peak of naratriptan was found well separated at 3.285 min.  
                   The developed method is economical, easy and it gives sharp peak with high 
resolution. The developed method is applied for the determination of naratriptan Hcl. The 
assay results comply to the label claim of the formulation. 
                   The developed method was validated as per ICH guidelines using parameters like 
Accuracy, Precision Linearity and Range, Specificity, Ruggedness, LOD, LOQ and 
Robustness. Hence the developed method is found to be satisfactory and it complies with all 
validation parameters. So this developed method can be used for the routine analysis of 
naratriptan Hcl in tablet dosage form. 
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